Results 111 to 120 of about 71,002 (280)

α2,3‐Sialyltransferase (ST3Gal1) regulates endometrioid‐type epithelial ovarian cancer cell migration and invasion via VEGF‐R2/JAK2/STAT3 signaling cascades

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To investigate the role of ST3 β‐galactoside α‐2,3‐sialyltransferase 1 (ST3Gal1) and vascular endothelial growth factor receptor 2 (VEGF‐R2) in endometrioid‐type epithelial ovarian cancer (E‐OC) because aberrant α2,3‐sialylation mediated by ST3Gal1 and VEGF‐R2‐related angiogenesis is linked with tumor progression. Methods ST3Gal1 and
Wei‐Ting Chao, Chia‐Hao Liu, Szu‐Ting Yang, Chen‐Hao Lin, Liang‐Wei Wang, Peng‐Hui Wang   +5 more
wiley   +1 more source

Is there an epigenetic component underlying the resistance of triple-negative breast cancers to PARP inhibitors?

Frontiers in Pharmacology, 2012
Poly(ADP-ribose)polymerase (Parp) is an enzyme responsible for catalyzing post-translational modifications through the addition of poly(ADP-ribose) chains (known as PARylation).
Amanda eLovato, Lawrence ePanasci, Michael eWitcher   +2 more
doaj   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

ADP-ribosylome analysis reveals homogeneous DNA-damage-induced serine ADP-ribosylation across wild-type and BRCA-mutant breast cancer cell lines

Cell Reports
Summary: ADP-ribosylation (ADPr) signaling plays a crucial role in DNA damage response. Inhibitors against the main enzyme catalyzing ADPr after DNA damage, poly(ADP-ribose) polymerase 1 (PARP1), are used to treat patients with breast cancer harboring ...
Holda Awah Anagho, Meeli Mullari, Aurél György Prósz, Sara Charlotte Buch-Larsen, Hayoung Cho, Marie Locard-Paulet, Zoltan Szallasi, Michael Lund Nielsen   +7 more
doaj   +1 more source

Beyond Tradition: An Integrated Toxicological, Ecological, and Public Health Perspective on Aristolochic Acids

Journal of Applied Toxicology, EarlyView.
ABSTRACT Aristolochia species have long been used in traditional medicine for their presumed anti‐inflammatory, analgesic and antimicrobial properties. However, extensive toxicological and epidemiological evidence now demonstrates that these plants contain aristolochic acids (AAs) I and II, highly potent nephrotoxic, genotoxic, and carcinogenic ...
Victor Ventura de Souza, Lara Rodrigues De Andrade, Tatiana da Silva Souza   +2 more
wiley   +1 more source

The PARP inhibitor AZD2461 provides insights into the role of PARP3 inhibition for both synthetic lethality and tolerability with chemotherapy in preclinical models [PDF]

, 2016
The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy. In BRCA1-deficient mouse models, olaparib resistance predominantly involves overexpression of P-glycoprotein,so ...
Aaron N. Cranston, Alan Lau, Attilla Ting, Bastiaan Evers, Charlotte Knights, David Rudge, Henry Brown, Janneke E. Jaspers, Jos Jonkers, Keith W. Caldecott, Lenka Oplustil O'Connor, Louise Jones, Marina Pajic, Mark J. O'Connor, Niall M.B. Martin, Rajesh Odedra, Robert H. Bradbury, Stuart L. Rulten, Sven Rottenberg   +18 more
core   +1 more source

Oncogenic KRAS Rewires Stress Granule Dynamics: Mechanisms and Therapeutic Opportunities

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Stress granules (SGs) are dynamic, membrane‐less structures that form in response to various cellular stresses, including metabolic, oxidative, and therapeutic challenges. They function as adaptive hubs and reorganize protein synthesis and signaling networks to help cells survive under stress. In cancer, these condensates are often hijacked to
Msimisi Ndzinisa, Birhanetensay Masresha Altaye, Yuh‐Pyng Sher   +2 more
wiley   +1 more source

Early Dapagliflozin and Melatonin Treatment Ameliorated LV Fibrosis via Suppressing TGF‐β1/Smads and Activating Nrf2‐ARE Signaling in MI Rodent

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study tested whether combined dapagliflozin (DAPA) and melatonin (Mel) therapy was superior to merely one for ameliorating the left ventricular (LV) fibrosis/remodeling and improving LV ejection fraction (LVEF) in rats after acute myocardial infarction (AMI). In vitro study demonstrated that DAPA treatment significantly suppressed the TGF‐
Jiunn‐Jye Sheu, Jui‐Ning Yeh, Han‐Tan Chai, John Y. Chiang, Chi‐Ruei Huang, Jun Guo, Hon‐Kan Yip   +6 more
wiley   +1 more source

Protocol for quantifying PARP inhibitor-induced changes in PARP1 dynamics and activity through live-cell imaging

STAR Protocols
Summary: Poly(ADP-ribose) polymerase 1 (PARP1) is a crucial DNA repair protein and a target of PARP inhibitors (PARPi), which suppress its catalytic activity while also altering its association with damaged chromatin. Here, we present a live-cell imaging
Petar-Bogomil Kanev, Sylvia Varhoshkova, Aleksander Aleksandrov, Stoyno Stoynov, Radoslav Aleksandrov   +4 more
doaj   +1 more source

Urologic Bacteriome: The Hero or the Villain in Prostate Cancer Onset, Progression, and Treatment?

Medicinal Research Reviews, EarlyView.
ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of cancer‐related mortality, presenting urgent unmet clinical needs in diagnosis and treatment. The recognition of the microbiome as a key factor in human health has prompted numerous studies, revealing an exciting new approach to ...
Lara R. S. Fonseca, Mariana Feijó, Cátia V. Vaz, Bruno J. Pereira, Sandra Laurentino, Ana Palmeira‐de‐Oliveira, Sílvia Socorro   +6 more
wiley   +1 more source